Olema Pharmaceuticals, Inc. (OLMA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 684.23M USD. 52-week range 6.65 to 36.26 USD. Data as of 2026-10-09.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 ...